Epidermal Growth Factor Recetor mutation study for 5 years, in a population of patients with non-small cell lung cancer;Estudo da mutação do recetor do fator de crescimento epidérmico, durante 5 anos, numa população de doentes com cancro do pulmão de não pequenas células

Revista Portuguesa de Pneumologia

Volumn 19, Issue 1, 2013, Pages 7-12

  Castro, A S ^a   Parente, B ^a   Goncalves I ^a   Antunes, A ^a   Barroso, A ^a   Conde, S ^a   Neves, S ^a   Machado, J C ^b  

^a CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Epidermal Growth Factor Receptor; Non Small Cell Lung Cancer; Survival; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERLOTINIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PATIENT; CANCER SURVIVAL; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; OVERALL SURVIVAL; SEQUENCE ANALYSIS; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84876705295     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rppneu.2012.08.002     Document Type: Article

References (18)

1. Parente B., Queiroga H., Teixeira E., Sotto-Mayor R., Barata F., Sousa A., et al. Estudo epidemiológico do cancro do pulmão em Portugal nos anos de 2000/2002. Rev Port Pneumol 2007 Mar, 13:255-265.
2. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R., Brannigan B., et al. 3 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
3. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gef itinib therapy. Science 2004, 304:1497-1500.
4. Mitsudomi T., Kosaka T., Endoh H., Yatabe Y., Kuwano H., Takahashi T., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gef itinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
5. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gef itinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
6. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Nat Cancer Inst 2005, 97:339-346.
7. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., Zamora L., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005, 11:5878-5885.
8. Han S.W., Kim T.Y., Hwang P.G., Jeon Y.K., Oh D.Y., Lee S.H., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cel lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501.
9. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005, 23:857-865.
10. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958.
11. Riely G., Politi A., Miller V., Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006, 12:7232.
12. Greulich H., Chen T.H., Feng W., Janne P., Alvarez J., Zappaterra M., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLOS Medicine 2005, 2:e313.
13. Penzel R., Sers C., Chen Y., Lehmann-Mühlenhoff U., Merkelbach-Bruse S., Jung A., et al. EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch 2011, 458:95.
14. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. Novel D761Y and common secondary T790M mutations in EGFR-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501.
15. Antunes A., Castro A., Campainha S., Gomes J., Barroso A., Conde S., et al. Novos métodos de abordagem no estudo do EGFR no CPNPC. Rev Port Pneumol 2011, 17:9-10.
16. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
17. Caicun Z., Yi-Long W., Gongyan C., Jifeng F., Xiao-Qing L., Changli W., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8 August):735-742.
18. Rosell R., Gervais R., Vergnenegre A., Massuti B., Felip E., Cardenal F., et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol 2011, 29.